Cargando…
(R)evolution: toward a new paradigm of policy and patient advocacy for expanded access to experimental treatments
In life-threatening conditions such as cancer and rare diseases, where there is no cure and no U.S. Food and Drug Administration (FDA)-approved therapy, patients sometimes seek access to an unapproved, experimental therapy through expanded access programs as their last, best hope for treatment to sa...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772317/ https://www.ncbi.nlm.nih.gov/pubmed/26926908 http://dx.doi.org/10.1186/s12916-016-0586-6 |